This afternoon we released our first Executive Informational Overview on Convoy Therapeutics, Inc., a closely held, late-stage biotechnology company developing a next-generation drug delivery technology. The report details Convoy's business, product development and R&D efforts, growth strategies and important milestones, management backgrounds, potential competition, and market opportunities, among many other factors that investors and stakeholders may find relevant.